Key facts
- This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Aug 2024, 18:27.
Pascal Touchon - 16 Aug 2024 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ATRA
- Reported as of
- 16 Aug 2024
- Net transaction value
- -$20,139
- SEC form
- 4
- Accepted by SEC
- 20 Aug 2024, 18:27:58 UTC
- Prior SEC filing
- 14 Aug 2024
- Next SEC filing
- 12 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Chao, Attorney-in-Fact for Pascal Touchon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Touchon filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 20 Aug 2024.
Change
- Previous filing in this sequence was filed on 14 Aug 2024.
- Current net transaction value: -$20,139.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATRA
transaction
Common Stock
Sale
- Transaction value
- $18,309
- Shares
- -2,762
- Change %
- -3.8%
- Price
- $6.63
- Shares after
- 70,403
- Date
- 16 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
ATRA
transaction
Common Stock
Sale
- Transaction value
- $1,830
- Shares
- -276
- Change %
- -0.39%
- Price
- $6.63
- Shares after
- 70,127
- Date
- 16 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
Footnote F2
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Footnote F3
This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.